LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Becton Dickinson and Co

Fechado

SetorSaúde

173.45 1.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

172.87

Máximo

173.69

Indicadores-chave

By Trading Economics

Rendimento

27M

330M

Vendas

104M

5.3B

P/E

Médio do Setor

32.766

51.198

EPS

3.35

Rendimento de Dividendos

2.46

Margem de lucro

6.259

Funcionários

70,000

EBITDA

93M

546M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+17.37% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.46%

2.40%

Próximos Ganhos

7 de ago. de 2025

Próxima data de dividendos

30 de jun. de 2025

Próxima data de ex-dividendo

9 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-17B

49B

Abertura anterior

171.8

Fecho anterior

173.45

Sentimento de Notícias

By Acuity

12%

88%

12 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Becton Dickinson and Co Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de mai. de 2025, 11:18 UTC

Ganhos

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

5 de fev. de 2025, 22:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 de nov. de 2024, 12:59 UTC

Ganhos

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 de nov. de 2024, 12:56 UTC

Ganhos

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 de mai. de 2025, 10:33 UTC

Ganhos

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 de mai. de 2025, 10:33 UTC

Ganhos

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 de mai. de 2025, 10:32 UTC

Ganhos

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 de mai. de 2025, 10:32 UTC

Ganhos

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 de mai. de 2025, 10:31 UTC

Ganhos

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 de mai. de 2025, 10:31 UTC

Ganhos

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

1 de mai. de 2025, 10:30 UTC

Ganhos

Becton Dickinson Updates full-Yr Fiscal 2025 Guidance and Provides Estimated Tariff Impact >BDX

1 de mai. de 2025, 10:30 UTC

Ganhos

Becton Dickinson Sees FY Adj EPS $14.06-Adj EPS $14.34 >BDX

1 de mai. de 2025, 10:30 UTC

Ganhos

Becton Dickinson 2Q Net $308M >BDX

1 de mai. de 2025, 10:30 UTC

Ganhos

Becton Dickinson 2Q EPS $1.07 >BDX

1 de mai. de 2025, 10:30 UTC

Ganhos

Becton Dickinson 2Q Adj EPS $3.35 >BDX

1 de mai. de 2025, 10:30 UTC

Ganhos

Becton Dickinson 2Q Rev $5.3B >BDX

5 de fev. de 2025, 21:56 UTC

Ganhos

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 de fev. de 2025, 21:54 UTC

Ganhos

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 de fev. de 2025, 21:54 UTC

Ganhos

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 de fev. de 2025, 21:53 UTC

Ganhos

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 de fev. de 2025, 21:30 UTC

Ganhos

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 de fev. de 2025, 21:30 UTC

Ganhos

Becton Dickinson 1Q Rev $5.2B >BDX

5 de fev. de 2025, 21:30 UTC

Ganhos

Becton Dickinson 1Q Net $303M >BDX

5 de fev. de 2025, 21:30 UTC

Ganhos

Becton Dickinson 1Q EPS $1.04 >BDX

7 de nov. de 2024, 11:36 UTC

Ganhos

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 de nov. de 2024, 11:35 UTC

Ganhos

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 de nov. de 2024, 11:30 UTC

Ganhos

Becton Dickinson 4Q EPS $1.45 >BDX

7 de nov. de 2024, 11:30 UTC

Ganhos

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 de nov. de 2024, 11:30 UTC

Ganhos

Becton Dickinson 4Q Rev $5.4B >BDX

7 de nov. de 2024, 11:30 UTC

Ganhos

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

Comparação entre Pares

Variação de preço

Becton Dickinson and Co Previsão

Preço-alvo

By TipRanks

17.37% parte superior

Previsão para 12 meses

Média 200.73 USD  17.37%

Máximo 255 USD

Mínimo 172 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Becton Dickinson and Co - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

4

Comprar

9

Manter

0

Vender

Pontuação Técnica

By Trading Central

167 / 206.99Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

12 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.